| |
Large-scale. Long-term. Maintenance studies in major depressive disorder are broad in scope, duration, and size. Build your optimal study plan and mitigate risk with the help of our guide. Learn more.
|
|
Today’s Big NewsOct 7, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now!
|
|
| By Gabrielle Masson As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with quarterly layoffs evening out to similar levels as the same time last year. |
|
|
|
By Nick Paul Taylor A phase 3 trial of Scholar Rock’s spinal muscular atrophy candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite the higher dose falling short of the targeted efficacy and Scholar Rock making no mention of a key secondary goal. |
By Darren Incorvaia The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA, the small RNA molecules that regulate genes, one year after the prize went to scientists who conducted foundational work on mRNA vaccines. |
By Nick Paul Taylor AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal, which covers a potential rival to an Eli Lilly prospect, positions AstraZeneca to run combination studies with an existing candidate it sees as a $5 billion-a-year blockbuster. |
|
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities.
|
|
By James Waldron The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study. |
By James Waldron A year after the failure of an idiopathic pulmonary fibrosis drug sent Galecto on a search for salvation, the Boston-based biotech has decided to go all-in on oncology and liver disease |
By Gabrielle Masson Taking the mat is Judo Bio, an Atlas Venture-backed biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney. |
By James Waldron RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its own IPO ambitions at $182 million. |
By James Waldron Psyence Biomedical has walked away from its planned acquisition of fellow Canadian psilocybin-based biotech Clairvoyant Therapeutics after completing the due diligence process. |
By Darren Incorvaia The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals, and even once treated it’s common for the microbe to reinfect patients again and again. |
By Fraiser Kansteiner Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said. Natco and Mylan—which is now part of Viatris—are working together on the development of a generic version of the massively popular diabetes drug. |
By Conor Hale MARAbio Systems derived its name from a particular pattern of antibodies carried by the child’s mother, which research has shown can react with proteins found in the developing brain. |
By Kevin Dunleavy Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey and one that may serve as instructive for future drug discovery. |
By Anastassia Gliadkovskaya Publicly available generative AI tools like ChatGPT are popular, easy to access and simple to use. If consumers are using them, are doctors, too? The answer, Fierce Healthcare finds, is yes. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
